Mario Cazzola
Department of Hematology Oncology
University of Pavia & Fondazione IRCCS Policlinico San Matteo
Pavia
Italy
Name/email consistency: high
- Prognostic classification and risk assessment in myelodysplastic syndromes. Cazzola, M., Malcovati, L. Hematol. Oncol. Clin. North Am. (2010)
- Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Cazzola, M., Della Porta, M.G., Malcovati, L. Hematology. Am. Soc. Hematol. Educ. Program (2008)
- Pyruvate kinase deficiency. Cazzola, M. Haematologica (2005)
- Role of ferritin and ferroportin genes in unexplained hyperferritinaemia. Cazzola, M. Best. Pract. Res. Clin. Haematol (2005)
- Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?. Cazzola, M. Nature Clinical Practice. Oncology (2004)
- Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Cazzola, M., Invernizzi, R., Bergamaschi, G., Levi, S., Corsi, B., Travaglino, E., Rolandi, V., Biasiotto, G., Drysdale, J., Arosio, P. Blood (2003)
- Erythropoietin therapy: need for rationality and active surveillance. Cazzola, M. Haematologica (2003)
- Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I., Coiffier, B. Br. J. Haematol. (2003)
- Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation. Cazzola, M., May, A., Bergamaschi, G., Cerani, P., Ferrillo, S., Bishop, D.F. Blood (2002)
- Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Cazzola, M., Cremonesi, L., Papaioannou, M., Soriani, N., Kioumi, A., Charalambidou, A., Paroni, R., Romtsou, K., Levi, S., Ferrari, M., Arosio, P., Christakis, J. Br. J. Haematol. (2002)